Article Details

Infinity Pharmaceuticals (NASDAQ:INFI) Earns Buy Rating from Analysts at Truist

Retrieved on: 2021-03-17 13:16:37

Tags for this article:

Click the tags to see associated articles and topics

Infinity Pharmaceuticals (NASDAQ:INFI) Earns Buy Rating from Analysts at Truist. View article details on hiswai:

Excerpt

Acadian Asset Management LLC now owns 647,394 shares of the biotechnology company's stock worth $758,000 after buying an additional 51,482 ...

Article found on: www.marketbeat.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up